Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 1
2000 1
2007 1
2009 5
2010 4
2011 5
2012 2
2013 7
2014 4
2015 2
2016 3
2017 1
2018 1
2019 1
2020 1
2021 3
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Dehydroepiandrosterone in systemic lupus erythematosus.
van Vollenhoven RF. van Vollenhoven RF. Rheum Dis Clin North Am. 2000 May;26(2):349-62. doi: 10.1016/s0889-857x(05)70142-3. Rheum Dis Clin North Am. 2000. PMID: 10768216 Review.
DHEA has shown promise for the treatment of SLE in three controlled and several uncontrolled clinical trials, including one large multicenter study comprising nearly 200 patients. ...Intriguing aspects of DHEA treatment in SLE that require further study are a possible bone …
DHEA has shown promise for the treatment of SLE in three controlled and several uncontrolled clinical trials, including one large mul …
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Stathis A, Tolcher AW, Wang JS, Renouf DJ, Chen LC, Suttner LH, Freshwater T, Webber AL, Nayak T, Siu LL. Stathis A, et al. Invest New Drugs. 2023 Jun;41(3):380-390. doi: 10.1007/s10637-022-01326-3. Epub 2023 Apr 11. Invest New Drugs. 2023. PMID: 37040046 Free PMC article. Clinical Trial.
Twenty-six patients (87%) experienced treatment-related adverse events (grade 3, 30%; no grade 4/5), most commonly diarrhea (67%), nausea (37%), and acneiform dermatitis (33%). Three patients (10%) experienced treatment-related adverse events leading to treatment di …
Twenty-six patients (87%) experienced treatment-related adverse events (grade 3, 30%; no grade 4/5), most commonly diarrhea (67%), nausea (3 …
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations.
Wang X, Luo Z, Chen J, Chen Y, Ji D, Fan L, Chen L, Zhao Q, Hu P, Sun P, Jia Z, Guo J, Si L. Wang X, et al. BMC Med. 2023 Jan 4;21(1):2. doi: 10.1186/s12916-022-02669-7. BMC Med. 2023. PMID: 36600247 Free PMC article. Clinical Trial.
Most frequency of grade 3 AEs were CK (14.2%), asthenia (7.1%), peripheral edema (4.8%), and acneiform dermatitis (4.8%). In the cohort of 12 mg twice daily dose (15 patients), confirmed objective response rate was 26.7%; disease control rate was 86.7%; median durat …
Most frequency of grade 3 AEs were CK (14.2%), asthenia (7.1%), peripheral edema (4.8%), and acneiform dermatitis (4.8%). In t …
Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.
Abdel-Rahman O, ElHalawani H, Ahmed H. Abdel-Rahman O, et al. Future Oncol. 2015;11(24):3307-19. doi: 10.2217/fon.15.265. Epub 2015 Nov 12. Future Oncol. 2015. PMID: 26561878 Review.
BACKGROUND: This meta-analysis was conducted aiming at assessing the risk of selected dermatological toxicities associated with MEK inhibitors. METHODS: We considered relevant prospective randomized Phase II and III trials of cancer patients on the three MEK inhibitors (tr …
BACKGROUND: This meta-analysis was conducted aiming at assessing the risk of selected dermatological toxicities associated with MEK inhibito …
Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).
Nishino K, Fujiwara Y, Ohe Y, Saito R, Miyauchi E, Kobayashi T, Nakai Y, Takahashi T, Shibata T, Hamaguchi T, Kikuchi K, Yamazaki N, Fukuda H, Nozawa K, Kiyohara Y. Nishino K, et al. Support Care Cancer. 2021 May;29(5):2327-2334. doi: 10.1007/s00520-020-05765-7. Epub 2020 Sep 11. Support Care Cancer. 2021. PMID: 32918131 Free PMC article. Clinical Trial.
Enrolled patients who developed facial acneiform rash within 2 weeks were randomized at second registration to either a ranking-UP (WEAK) group or a ranking-DOWN group. ...CONCLUSION: In NSCLC patients who received EGFRIs, preemptive therapy of oral minocycline and heparin …
Enrolled patients who developed facial acneiform rash within 2 weeks were randomized at second registration to either a ranking-UP (W …
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L, Zhang W, Fan N, Cao P, Cheng Y, Zhu L, Luo S, Zong H, Bai Y, Zhou J, Deng Y, Ba Y, Liu T, Aili M, Yin X, Gu K, Dai G, Ying J, Shi J, Gao Y, Li W, Yu G, Xie L, Gai W, Wang Y, Meng P, Shi Y. Yang L, et al. EBioMedicine. 2024 Feb;100:104966. doi: 10.1016/j.ebiom.2024.104966. Epub 2024 Jan 13. EBioMedicine. 2024. PMID: 38217945 Free PMC article. Clinical Trial.
The most common grade 3 treatment-related adverse events (TRAEs) were hypomagnesemia (17%, 19/110) and acneiform dermatitis (11%, 12/110). No deaths occurred. Genomic analysis suggested positive association between MYC amplification and patients' response (P = 0.005 …
The most common grade 3 treatment-related adverse events (TRAEs) were hypomagnesemia (17%, 19/110) and acneiform dermatitis (1 …
Facial dermatitis in a healthy 9-year-old boy.
Hiep A, Gross E. Hiep A, et al. JAAPA. 2022 Sep 1;35(9):37-40. doi: 10.1097/01.JAA.0000854540.40254.d0. JAAPA. 2022. PMID: 36007117
He had previously been prescribed mometasone cream for rosacea, which his mother applied daily for about 45 days. After a biopsy was performed, he was diagnosed with acneiform dermatitis likely secondary to topical corticosteroid use complicated by demodex folliculi …
He had previously been prescribed mometasone cream for rosacea, which his mother applied daily for about 45 days. After a biopsy was perform …
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
Brueckl WM, Reck M, Schäfer H, Neben K, Griesinger F, Rawluk J, Krüger S, Kokowski K, Ficker JH, Möller M, Schueler A, Laack E. Brueckl WM, et al. J Geriatr Oncol. 2023 Jan;14(1):101394. doi: 10.1016/j.jgo.2022.10.009. Epub 2022 Oct 30. J Geriatr Oncol. 2023. PMID: 36323612 Free article.
In the 70 years age group and the <70 years age group, grade 3 adverse drug reactions (ADRs) were observed in 34.8% and 40.7% of patients, respectively; the most common were diarrhea (13.6% and 14.0%), acneiform dermatitis (7.6% and 7.0%), stomatitis (1.5% and 4. …
In the 70 years age group and the <70 years age group, grade 3 adverse drug reactions (ADRs) were observed in 34.8% and 40.7% of patients …
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E. Delord JP, et al. Target Oncol. 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0. Target Oncol. 2021. PMID: 33170484 Clinical Trial.
DLTs were mainly observed at doses 120 mg/day and included skin rash/acneiform dermatitis and ocular events, such as serous retinal detachment. ...CONCLUSIONS: Based on the safety profile and efficacy signals, a continuous bid regimen was the preferred dosing schedu …
DLTs were mainly observed at doses 120 mg/day and included skin rash/acneiform dermatitis and ocular events, such as serous re …
The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
Trullas A, Delgado J, Koenig J, Fuerstenau U, Dedorath J, Hausmann S, Stock T, Enzmann H, Pignatti F. Trullas A, et al. ESMO Open. 2021 Feb;6(1):100031. doi: 10.1016/j.esmoop.2020.100031. Epub 2021 Jan 8. ESMO Open. 2021. PMID: 33422765 Free PMC article. Review.
On 2 June 2020, a marketing authorisation valid through the European Union (EU) was issued for encorafenib in combination with cetuximab in adult patients with metastatic colorectal carcinoma (mCRC) with the BRAFV600E mutation who had received prior systemic therapy. Encorafenib …
On 2 June 2020, a marketing authorisation valid through the European Union (EU) was issued for encorafenib in combination with cetuximab in …
39 results